UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                   FORM 10-KSB

|X|   ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
      1934

                                        For the Fiscal Year ended April 30, 2005

                                        Commission File Number 000-33473

                               VIRIDAX CORPORATION
--------------------------------------------------------------------------------
                 (Name of Small Business Issuer in its charter)

           FLORIDA                                      65-1138291
      ------------------                           -------------------
(State or other jurisdiction of            (I.R.S. Employer Identification No.)
Incorporation or organization)

             270 NW 3rd Court
           Boca Raton, Florida                           33432-3720
---------------------------------------       ---------------------------------
(Address of principal executive offices)                 (Zip Code)

Issuer's Telephone: (561) 368-1427

Securities registered under Section 12(g) of the Exchange Act:

                                     Common
--------------------------------------------------------------------------------
                                (Title of Class)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports, and (2) has been
subject to such filing requirements for the past 90 days Yes |X| No |_|

Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. |X|

State Issuer's revenues for its most recent fiscal year.        None
                                                         ----------------

The Aggregate market value of voting and non-voting common equity held by
non-affiliates computed by reference to the price at which the common equity was
sold within the past 60 days is $1,690,000.

State the number of shares outstanding of the issuer's common equity as of April
30, 2005: 5,940,000.

Transitional Small Business Disclosure Format:     No


                                       1
<PAGE>

                                     PART I

ITEM 1. DESCRIPTION OF BUSINESS

      (a) BUSINESS DEVELOPMENT

      The Company was originally formed under the name of MEDIA ADVISORY GROUP,
INC., as a Florida corporation filed July 1, 1998. The Company was assigned
Document Number P98000058690.

      The Company was formed for the original purpose of providing various media
consulting services. However, the Company never activated services and remained
inactive. On September 24, 1999, the Company was administratively dissolved for
failure to file an annual report.

      On July 6, 2001 an application for Corporation Reinstatement, together
with payment of applicable fees, was filed with the Florida Department of State.
The Company was reinstated on July 23, 2001.

      On August 6, 2001 Articles of Amendment were filed with the Florida
Department of State, changing the name to: I & E TROPICALS, INC. and changing
the authorized capital stock of the Company to Fifty Million (50,000,000) shares
of voting common stock at a par value of $.001 per share.

      The above referenced Articles of Incorporation, the Reinstatement of Media
Advisory Group, and the amendment to the Articles of Incorporation changing the
name to I & E Tropicals, Inc. are listed herein in ITEM 13 (Exhibits) and
incorporated by reference as stated in the Index to Exhibits.

      On April 5, 2005 Articles of Amendment were filed with the Florida
Department of State, changing the name of the Company to: VIRIDAX CORPORATION
and changing the authorized capital stock of the Company to add Three Million
(3,000,000) shares of Class A Preferred Stock at a par value of $1.00. This
amendment is included as an Exhibit (3(i)(d) at Page Number starting at E-9.

      The Bylaws of the Company are listed herein in ITEM 13 (Exhibits) and
incorporated by reference as stated in the Index to the Exhibits.

      On April 24, 2005 Viridax, Inc. entered into an agreement (more
particularly described in (b) of this ITEM 1) whereby Viridax purchased certain
bacteriophage-based products from Mycobis Corporation (a private corporation) in
exchange for 2,000,000 shares of Viridax common stock. This Asset Purchase
Agreement is included as Exhibit (ITEM 13) Number 10 starting at Page Number
E-30


                                       2
<PAGE>

      (b) BUSINESS OF ISSUER

      The primary business of the Company (operating under the former name of I
& E Tropicals, Inc.) has been the import/export of exotic marine life from the
Bahamas to the Company in Florida for subsequent sale to end-use customers.
However, due to a lack of funding the Company has been unable to continue its
operations and has remained inactive since the end of its fiscal quarter ending
October 31, 2002.

      In April, 2005 a business arrangement was reached whereby (1) the Company
would purchase certain bacteriophage-based products in exchange for 2,000,000
shares of its common stock, (2) the Company name would be changed to Viridax
Corporation, and (3) new management would be put in place to operate the Company
in the course of its new primary business direction. While corporate emphasis
will be placed upon the bacteriophage products, the Company does intend to
continue its original business of importing and exporting exotic marine life as
funding surplus will permit.

      Viridax Corporation (Viridax) is a biopharmaceutical discovery and
development company formed to expedite the commercialization of new technologies
and products for the treatment of bacterial infectious diseases, especially
antibiotic-resistant infections. The bacteriophage-based technologies under
development by Viridax specifically target bacterial pathogens that incite
resistant infections in substantial human populations.

      In particular, the Company is developing specific bacteriophage products
for the treatment of bacterial infections incited by Staphylococcus aureus and
other Staphylococcal species encountered in the community setting and as
nosocomial (hospital-acquired) agents. Many strains of Staphylococcus aureus and
other Staphylococcal species are now resistant to most commercially-available
antibiotics. The health threat and economic consequences of common Staph
infections are now catastrophic areas of both the developing and the developed
world.

      White it is the intention of the Company to develop its products for
treatment in the United States, the Company does have the option of opening a
Phage Therapy Center outside of the United States and offering immediate
treatment using its now developed bacteriophage products. Phage therapy Centers
now operate in Tbilisi, Republic of Georgia and in Tijuana, Mexico. The
treatment centers in Tbilisi and Tijuana are owned by Phage International, Inc.
(See www.phagetherapy.org/). If the company should so desire a number of
additional countries will permit these treatment centers.

      Stapyhlococcus aureus (S. aureus or Staph) is a common infectious
bacterium, typically encountered on the skin and in the nasal passages of
healthy people. Staph can cause serious infections of the bone, soft tissue,
eye, respiratory tract and blood stream, and it is one of the most common causes
of skin infections.

      1. PRODUCTS

      Viridax plans to bring forward a series of high value biopharmaceutical
products based on the development of new and modified bacteriophages including
certain proprietary delivery technologies. Viridax's first products are being
developed for the treatment of Staphylococcus aureus, astaphylococcal spp.


                                       3
<PAGE>

Leading Product Candidates:

         Staphylococcus aureus Bacteriophage
         (Respiratory and Systemic Infection Products):

         Staph Respiratory Infections
         Staph Systemic Infections

         Staphylococcus aureus Bacteriophage
         (Wound Infection Products)

         Abrasion, Diabetic Ulcer and Bed Sore Infections
         Surgical and Trauma Wound Infections

         Viridax currently has several forms of the retained stocks of its
Staphylococcal "Product Candidate" Bacteriophage maintained in incubators as
suspensions of bacteriophage in USP physiological saline at concentrations of
about 10E9 - 10E10, at a monitored temperature of 4 degrees C, which is their
optimal temperature for long-term stability. This Product Candidate
Bacteriophage stock represents the core intellectual property and biological
materials of Viridax, and is the retained source material for the Company's
first series of products for the treatment of ophthalmic, respiratory, systemic
and topical Staph infections in humans.

         Regulations of the US Food and Drug Administration prohibit the sale or
use of Out-of-date, previously-manufactured, therapeutic products, either
through interstate or international commerce. Therefore, Viridax does not
maintain stores of previously-manufactured product. However, the Product
Candidate Bacteriophage biological materials retained by Viridax will be used as
core starting material for fermentation scale-up manufacturing of the Product
Candidate Bacteriophage "Drug Substance" when operations are initiated. The
Viridax Product Candidate Bacteriophage is a biological material in the form of
a bacterial virus (i.e., a lytic bacteriophage) that will be amplified by
fermentation manufacturing using the mass-culture of cells of a specific
proprietary strain of the host bacterium, Staphylococcus aureus.

         2. ESTIMATED MARKETS

         The international infectious disease therapeutics market grew from
about $16 billion in 1991 to more than $43 billion in 2002, and it continues to
grow. The US market share has grown from about 31% to about 37%, while the
Japanese market share has declined from about 26% to 21%. The European market
share and the markets in the world have remained nearly stable during that
period, with Europe represented by a 28% market share, and the rest of the world
about 15%. The US market share for new generation antibiotics alone is
anticipated to exceed $12 billion within the next year. This phenomenal growth
continues in spite of the fact that bacteria have now developed resistance to
nearly all of the antibiotic agents that represent the product growth leaders.
This has led to a continual stream of new antibiotic products introduced to the
market, many of which have a greatly shortened product life as a direct result
of the more-rapid development of resistance by the target infectious bacteria.


                                       4
<PAGE>

         In US hospitals it is estimated that perhaps 3,000,000 patients are
infected each year by bacterial pathogens, and from 80,000 to 100,000 people die
from infections, compared with a yearly mortality of about 8,000 in the early
1990s by infectious diseases. About 90% of Staphylococcal infections, which are
responsible for about 15% of all bacterial infections are now resistant to
Penicillin, and 40-65% are resistant to methicillin.

         3. DEVELOPMENTAL STRATEGY

         Essential to the successful scale-up manufacturing of therapeutic
products for preclinical and clinical testing, regulatory approval and
commercial sale is the establishment of current Good Manufacturing Practices
(cGMP) systems of manufacturing that will result in the reproducible
manufacturing of pharmaceutical products. Viridax managers have substantial
expertise in the cGMP manufacturing of pharmaceutical products, and plan to have
its initial products manufactured by contract at a facility in compliance with
ICH cGMP regulations.

         The bacteriophage products are considered as biologicals by US FDA and
UK MCA standards and guidelines. Viridax has experience in establishing systems
to these standards. Scale-up cGMP batches of therapeutic phage for clinical use
will be subcontracted to a contract manufacturing organization having direct
experience with biopharmaceutical products.

         Viridax has developed a manufacturing relationship with a contract
manufacturing facility in the U.S. that is prepared to initiate scale-up
manufacturing to specifications required by Viridax for manufacturing of the
first Staph page product in full compliance with USFDA guidelines. The Company
has inspected the facility and intends to execute a contract manufacturing
agreement upon achieving adequate funding.

         4. COMPETITION / RISK

         Competition for the Viridax technology products and markets is
represented by any and all pharmaceutical and biotechnology companies that
discover, make and sell antibiotic products for the treatment of infectious
diseases. The competition that may be faced by Viridax during the discovery,
development and marketing of its products will be represented by a combination
of elements. Competition may be encountered from the discovery and invention of
new antibiotics that may be analogs or derivatives of existing antibiotics to
which resistance genes have not yet been expressed, or by new classes of
antibiotics for which there may not yet exist resistance mechanisms within the
genome. Such successes are unlikely, but could represent serious competition to
Viridax.

         Greater competition to Viridax could be the emergence of new classes of
agents that may represent novel biological mechanisms of action for which
resistance mechanisms are unlikely events. Such an event could be the
development of a new strategy for antibiosis employing novel biochemical
mechanisms that would reduce lysis within bacterial cells, and that could mimic
lysozyme activity, or that perhaps could incite lytic activity within the
bacterial cell, and that perhaps could be gene mediated. Also, there are new
classes of naturally occurring biological agents being investigated that induce
the formation of pores in bacterial cell membranes and cell walls, and that
could also result in a form of cell lysis. Viridax is currently unaware of any


                                       5
<PAGE>

company or technology that may represent immediate or direct competition to its
technology or products , but it must be assumed that technologically-competent
scientists and companies are working to discover and develop new technologies
and products that will be competitive with those of Viridax.

         There are currently several US and international biotechnology
companies that are exploiting bacteriophage as therapeutic agents, plus a number
of academic investigators. Most of the firms are seeking to develop
bacteriophage for the treatment of animal disease, while others seek to develop
antiseptic and disinfectant products using bacteriophage as the active
ingredient. There are only a few companies that exclusively seek to develop
therapeutic bacteriophages.

         Biophage, Inc. - Montreal, Canada www.biophage.com. Biophage exploits
new platform technologies in the health industry, with focus on cancer,
infectious diseases, inflammation and immune modulation. Therapeutic
bacteriophage is a minor emphasis.

         Biopharm Pharmaceuticals - Tbilisi, Georgia biopharm@got.ge Biopharm
acquired the phage production plant of the Eliava Institute. They make vitamins,
various biomedical reagents, probiotics, and about 20 liters a month of phage
products for local use.

         Exponential Biotherapies, Inc. - Port Washington, NY and Rockville, MD
carltonebi@erols.com Exponential is developing bacteriophage for human
infectious diseases, plus for food production and companion animals. Founded in
1993 Exponential was the first American company devoted to phage therapy. They
have successfully completed a Phase I clinical trial.

         GangaGen - GangaGen Biotechnologies, Ltd., Bangalore, India ; GangaGen,
Inc., Palo Alto, CA ; GangaGen Life Sciences, Inc., Ottawa, Canada
www.gangagen.com GangaGen emphasizes the diagnosis, treatment and prevention of
nosocomial infections, secondary infections, and topical infections. They plan
to use bacteriophage technology to discover new treatments for enteric
infections, as well as upper respiratory tract infections.

         Hexal Gentech - Holzkirchen, German - www.hexal-gentech.com Hexal
develops novel bacteriophage therapeutics for the treatment of multidrug
resistance bacterial infections. They emphasize the use of bacteriophage that
are engineered to package anti-bacterial plasmids.

         Intralytics, Inc. - Baltimore, MD www.intralytix.com Intralytics is a
biotechnology company focused on the production and marketing of products using
bacteriophages to control bacterial pathogens in environmental, food processing
and medical settings.

         MicroPeace Biotechnology Consulting - Melbourne, AU
micropeace@hotmail.com MicroPeace is developing new compounds for the treatment
of drug-resistant bacteria. They search for new classes of compounds in novel
bacteria. They isolate rare bacteria as a service for industrial microbiologists
who search for novel compounds with therapeutic activity.


                                       6
<PAGE>

         Novolytics Limited - Warwick, Coventry, UK www.novolytics.co.uk
Novolytics was formed in 2002 as a spin-out from the University of Warwick,
Coventry, UK, to exploit the results of their research into the use of
bacteriophages to combat bacterial infection, initially antibiotic-resistant
Staph infections.

         Phage Biotech, Ltd. - Tel Aviv, Israel www.page-biotech.com Phage
Biotech focuses on the development, standardization, production and application
of lytic bacteriophage technology toward an array of clinical, veterinary,
agricultural, industrial and ecologic applications. They are conducting
pre-clinical studies of Psuedomonas Keratitis and Endophthalmitis phage
treatments.

         Phage Tech, Inc. - Montreal, Canada www.phagetech.com PhageTech is a
biopharmaceutical company focused on the discovery and development of new
classes of antibiotics for novel antibacterial targets based on phage genomics.
PhageTech identifies proteins used by the phages to kill bacteria, plus the
specific bacterial targets against which those proteins interact.

         Phage International, Inc. Los Altos, California 94024
www.phageinternational.com Phage International was formed in July of 2004. The
company's goal is to become a primary marketer of bacteriophage therapies in the
western world.

         Other Risk Factors

         It has been established that Viridax Corporation may face serious
competition coming from new discoveries of antibiotics or new classes of agents.
In addition to such considerations Viridax Corporation faces a number of risk
factors, some of which are outlined below:

         o        In order to move ahead to establish clinical trials it will
                  require considerable funding. There is no assurance that such
                  funding may be obtained, either from joint venture partners or
                  sales of the Company stock.

         o        Viridax Corporation is in the development stage and its
                  proposed operations are subject to all of the risks inherent
                  in the establishment of a new business. The Company has no
                  operating revenues and none are expected until such time as
                  the products are fully tested and approved in the U.S. There
                  can be no assurance that the Company will ever achieve
                  profitability.

         o        The Company is totally dependent upon the technical and
                  management skills of its present officers and directors. No
                  provision has been developed to keep these key personnel or to
                  offset their loss with adequate reserves or insurance.

         o        The Company is not trading under any venue of the NASD.
                  Consequently, the investor has no present means to gain a cash
                  return on their investment. Also, there is no present prospect
                  for a sale of the Company. And if the Company should commence
                  trading there is no way to determine the price per share on
                  any consistent basis.


                                       7
<PAGE>

         o        Our ability to raise additional financing depends on many
                  factors beyond our control, including the state of capital
                  markets, the status of our business and the development or
                  prospects for development of competitive business operations
                  by others. The necessary additional financing may not be
                  available to us or may be available only on terms that would
                  result in further dilution to the current owners of our common
                  stock. If we are unable to raise additional funds when we need
                  them, we may have to curtail or discontinue our operations.

         o        We have not paid any dividends on our common stock and do not
                  anticipate paying cash dividends in the foreseeable future.
                  Management intends to retain any earnings to finance the
                  growth of its business. Management cannot assure you that the
                  company will ever pay cash dividends. Accordingly, holders of
                  our common stock will have to rely on the appreciation thereof
                  and the ability to sell shares on the public market or as a
                  private sale to realize any monies from holding the Company
                  stock.


         REGULATORY CONSIDERATIONS

         The Viridax' products will be regulated by governing authorities in the
United States, the UK and the EU, and other countries, both within the
International Conference on Harmonization (ICH) and without, according to the
country's local regulatory requirements. The regulatory process in European
Community (EEC) is similar to that in the USA. The clinical trials process is
initiated by filing a CTX (the US equivalent is the Investigational New Drug
Application or IND) for therapeutic products with the Medicines Control Agency
(MCA), which is analogous to the US Food and Drug Administration (FDA). The MCA
application dossier contains, among other sections, (1) A summary of the
dossier, (2) Chemical, pharmaceutical and biological documentation, (3)
Pharmacotoxicolological documentation; and, (4) Clinical trials documentation,
all of which are similar to the US counterpart.

         In the US, such products are regulated by the US Food and Drug
Administration (FDA) pursuant to the federal Food, Drug and Cosmetic Act and the
Public Health Service Act. These regulations govern preclinical and clinical
testing conducted to establish safety and effectiveness, product licensure prior
to marketing, and manufacturing compliance. In addition to FDA regulations, the
Company is also subject to other federal and state regulations, such as the
occupational Safety and Health Act and the Environmental Protection Act. The
major steps required before a pharmaceutical agent may be marketed in the US
include (1) preclinical testing, (2) submission to the FDA of an IND, which must
become effective prior to commencing human clinical trials, (3) the performance
and evaluation of scientifically-valid and well-controlled human clinical trials
to establish safety and efficacy, (4) submission of a New Drug Application (NDA)
or a product License Application (PLA) to the FDA, and (5) FDA approval of the
NDA or PLA prior to product commercialization. In additional to obtaining FDA
approval for each product, each drug manufacturing establishment must undergo
pre-approval inspection by the FDA.


                                       8
<PAGE>

         The Company regulatory strategy is to expedite clinical trials, to
enable registration and marketing approval through MCA and FDA sanctioned
accelerated review and approval mechanisms for products for life-threatening
diseases or products with a compelling pharmacoeconomic benefit. All preclinical
studies will be conducted in compliance with FDA current Good Laboratory
Practices (cGLP) guidelines, as well as international standards for worldwide
licensing. It should be noted that the Company has the alternative development
option of selling its products outside the United States should it encounter
difficulties in complying with federal requirements that are now unforeseen.

         EMPLOYEES

         At the present time, the Company President is the only full-time
employee. He is not currently drawing a salary.

         CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

         This report contains forward-looking statements within the meaning of
Section 27A of the Securities Act and Section 21E of the Exchange Act. We have
based these forward-looking statements largely on our current expectations and
projections about future events and financial trends affecting the financial
condition of our business. These forward looking statements are subject to a
number of risks, uncertainties and assumptions, including, among other things:

         o        Our ability to obtain capital;

         o        Our ability to fully implement our business plan;

         o        General economic and business conditions, both nationally and
                  in our markets;

         o        Our expectations and estimates concerning future financial
                  performance, financing plans and the impact of competition;

         o        Anticipated trends in our business;

         o        Other risk factors set forth under "Other Risk Factors" in
                  this report.

         In addition, in this report, we use words or phrases such as "high
value", "plans," "expects," "future," "intends," and similar expressions to
identify forward-looking statements.

         We undertake no obligation to update publicly or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise after the date of this report. In light of these risks and
uncertainties, the forward-looking events and circumstances discussed in this
report may not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.


                                       9
<PAGE>

ITEM 2.   DESCRIPTION OF PROPERTY

         The Company owns no real property, nor does it have any leasehold
interests at this time.

         The Company executive offices are provided, without payment of rent at
this time at 270 NW 3rd Court, Boca Raton, Florida. This address is the location
of the offices of Ledyard H. DeWees, P.A., the law firm representing Viridax
Corporation which has agreed to provide office space and secretarial assistance
without charge.

ITEM 3.  LEGAL PROCEEDINGS

         There is no litigation of any type whatsoever pending or threatened by
or against the Company, its officers and/or its directors.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         On February 15, 2005, the Board of Directors approved a resolution that
the corporation change its name to Viridax Corporation and change the authorized
capital stock to add 3,000,000 shares of Class A Preferred Stock at a par value
of $1.00 per share, subject to the approval of stockholders having a voting
majority interest of all outstanding stock. Consistent with this Resolution a
Schedule 14C was filed with the Securities and Exchange Commission and mailed to
all stockholders of record on February 15, 2005, informing them of the proposed
amendments to the Articles of Incorporation. No proxies were solicited and the
stockholders were requested not to send proxies to the management.

         As explained in the Schedule 14C Information Statement, Florida Statute
Section 607.0704 provides that when action is taken by those shareholders,
without a meeting, having the necessary minimum votes that would be necessary to
take such action at a meeting where all voting groups entitled to vote thereon
were present and voted, the Corporation must notify its shareholders within ten
days after receiving written authorization by those persons holding a majority
of the outstanding voting common stock approving the actions taken without a
meeting.

         The Company received the above-referenced authorizations to change the
Company name and add the specified preferred stock on March 1, 2005 by
stockholders owning 76.92% of all outstanding voting stock. Accordingly, after
compliance with the notice requirements of Schedule 14C, the amendments were
submitted to the Florida Department of State and filed on April 5, 2005.


                                       10
<PAGE>

                                     PART II

ITEM 5.  MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

         (A)      MARKET INFORMATION

         There is no public trading market for the Company's stock and
management has not undertaken any discussions, preliminary or otherwise, with
any prospective market maker regarding a public market for the stock.

         (B)      HOLDERS

         There are 29 shareholders of record of the Company's common stock.

         (C)      DIVIDENDS

         The Company has not paid any dividends to date and has no plans to do
so in the foreseeable future.

         (D)      SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION
                  PLANS.

         None.

         (E)      RECENT SALES OF UNREGISTERED SECURITIES

         On April 24, 2005 the Company executed an Asset Purchase Agreement with
Mycobis Corporation, a private company, whereby Viridax purchased certain
bacteriophage-based products in exchange for 2,000,000 shares of its common
stock. A copy of this Agreement is provided as Exhibit (3)(1)(d) at Page Number
E-9. The Company claimed exemption from registration pursuant to Section 4(2) of
the Securities Act of 1933, as amended, (the "Act") as being a transaction by
the issuer not involving any public offering. In consideration of the factors in
determining whether a transaction is a public offering, such factors being (1)
the number of the offerees and their relationship to each other and to the
issuer, (2) the number of units offered, (3) the size of the offering, (4) the
manner of the offering, the Company takes the position that because the number
of offerees was one, the shares as issued were restricted, and the manner of the
offering was a business transaction under direct negotiation between the two
parties, no public offering was involved.

         By approval of the Board of Directors, on April 15, 2005 the Company
sold 25,000 shares of its common stock to an unrelated non-affiliated individual
for the cash price of $25,000.00 and on April 29,2005 the Company sold 15,000
shares of its common stock to an unrelated non-affiliated individual for the
cash price of $15,000.00. In both situations, the Company claims an exemption
under Section 4(2) of the Act, based on the factors as set forth above, the
Company takes the position that these two separate sales were sales not
involving a public offering, The purpose of the 4(2) exemption was to permit an
issuer to make a specific or isolated sale of its securities to particular


                                       11
<PAGE>

persons without incurring the expense of registration. That is precisely the
situation in the sales identified above to sophisticated investors.

ITEM 6.  PLAN OF OPERATION

         The plan of operation for Viridax over the next twelve months, assuming
adequate funding, is to enter into an agreement with a Contract Research
Organization (CRO) to have that Organization implement the following procedures
with the Company's Lead Product Candidate ( Staph aureus Phage - R1):

         o        Scale-up Fermentation Manufacturing to cGMP

         o        Drug Substance Purification

         o        Analytical Methods Development ( Identity, Purity, Potency)

         o        Genomics ( Sequencing, Bioinformatics, Microarray Technology)

         o        Stability Studies ( Drug Substance and Finished Product)

         o        Phage Banking and Host Bacterial Cell Banking

         o        Documentation (Laboratory, Manufacturing, Regulatory, Quality)

         o        Formulations Development (for Delivery)

         The objective behind the out-sourcing to a CRO is obtain a product to
be used in Phase I and Phase II clinical trials,

         The Company estimates that it will take twelve months to complete the
Formulations Development and thus be ready for regulatory filings and actual
clinical trials, The Company further estimates that it will cost approximately
$1.5 million dollars to complete the steps as outlined above through the
formulations development,

         Because the Company President is the only full-time employee and has
agreed to serve without compensation until such time as proper funding is
obtained and other operational cash requirements are minimal, the Company feels
that it can maintain itself until funding is obtained.


ITEM 7.  FINANCIAL STATEMENTS

         Attached audited financial statements for Viridax Corporation, for the
year ended April 30, 2005 are submitted in compliance with Item 310 of
Regulation S-B.

ITEM 8. CHANGES IN AND DISAGREEMENT WITH ACCOUNTANTS ON
        ACCOUNTING AND FINANCIAL DISCLOSURE.

         Not applicable.


                                       12
<PAGE>

ITEM 8A.       CONTROLS AND PROCEDURES

         Under the supervision and with the participation of management,
including the Chief Executive Officer, as the primary Executive Officer, we
evaluated the effectiveness of the design and operation of our disclosure
controls and procedures (as defined in Rule 13a-15(e) under the Securities
Exchange Act of 1934 (the "Exchange Act")). Based on that evaluation, our Chief
Executive Officer has concluded that, as of the end of the period covered by
this report, our disclosure controls and procedures are adequately designed to
ensure that the information required to be disclosed by us in the reports we
file or submit under the Exchange Act is recorded, possessed, summarized and
reported, within the time periods specified in the applicable rules and forms.
During the period covered by this Annual Report on Form 10-KSB, there was no
change in our internal control over financial reporting (as defined in Rule
13a-15(f) under the Exchange Act) that materially effected, or is reasonably
likely to materially effect, our internal control over financial reporting.

ITEM 8B.   OTHER INFORMATION

                 Not applicable


                                    PART III

ITEM 9.    DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
           COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT

    (A)    IDENTIFY DIRECTORS AND EXECUTIVE OFFICERS

Name                      Age      Position

Richard C. Honour         65       President, Chief Executive Officer

                                   Director, Chairman

Ledyard H. DeWees         73
                                   Secretary

Michael C. Maloney        55
                                   Director

Javid Sheikh              51
                                   Director

Brett L. DeWees           39
                                   Director

         Richard C. Honour, Ph.D., President and CEO, Director

         From 1997-2002, Dr. Honour served as the President and CEO of Phage
Therapeutics, Inc. and Phage Therapeutics International, Inc. companies involved
in the discovery and development of bacteriophage pharmaceutical products for
the treatment of antibiotic-resistant and other bacterial infections. In 2003 he
served as a Director of Phage Genomics, Inc., a company also involved in the
discovery and development of bacteriophage pharmaceutical products for the
treatment of antibiotic-resistant and other bacterial infections. In 2002, to


                                       13
<PAGE>

the present day he is a Director of Eulara Corporation, a company that develops
and markets skin care products and dietary supplements. He is also the current
President of Mycobis Corporation, a Florida biopharmaceutical company formed to
discover and develop bacteriophage therapeutic agents for the treatment of
antibiotic-resistant and sensitive bacterial pathogens. Dr. Honour was named to
the Board of Directors on April 25, 2005.

         Ledyard H. DeWees, Esq., Secretary

         Mr. DeWees is an attorney and a member of the Florida Bar since 1959.
For the past five years he has limited his practice to corporate and securities
laws. He was named as Secretary on April 25, 2005.

         Michael C. Maloney, RAC, Director

         Mr. Maloney has 28 years of experience in FDA regulated medical
products including medical devices, in vitro diagnostics, drugs, biologics,
critical care monitoring equipment and contract manufacturing. He was President
and CEO of La Haye Laboratories, Inc. from 1997-2001 and President and CEO of
Emerald Pharmaceuticals, L.P. from 2001-2004. He is currently Senior Regulatory
Affairs Specialist of ZymoGenetics, Inc. Mr. Maloney holds a BA in Biological
Sciences from San Jose State University and is regulatory affairs certified
(RAC) through the Regulatory Affairs Professional Society. He was named to the
Board of Directors on April 25, 2005.

         Javaid L Sheikh, MD, MBA, Director

         Dr. Sheikh. has served as Associate Professor of Psychiatry, Stanford
School of Medicine, from 1993 to the present day. From 1997 to the present he is
also the Associate Chief of Staff for Mental Health, Veterans Affairs Palo Alto
Health Care System and Staff Physician, Psychiatry Service, VA, Palo Alto Health
Care System. In addition to his university teaching, research and physician
practice responsibilities, Dr. Sheikh is also Scientific Advisor and Consultant
for seven multinational pharmaceutical companies. He is the author or co-author
on more than 100 peer-reviewed articles and abstracts in various fields of
psychiatry and behavioral sciences. He was named to the Board of Directors on
April 25, 2005. Dr. Sheikh is also a Director of Liska Biometry, a reporting
company.

         Brett L. DeWees, Director

         Since 2001, Brett DeWees has served as the President and Director of
Viridax Corporation. In addition to his duties as a Director of Viridax, Mr.
DeWees is the President and CEO of Underwater Marine Collectors, Inc. a Florida
corporation whose primary activity is the collection of exotic marine life,
since June 2003.

         (B)    Family Relationships

         Brett DeWees, Director, is the son of Ledyard H. DeWees, Secretary.
There are no other family relationships


                                       14
<PAGE>

         (C)   INVOLVEMENT IN CERTAIN LEGAL PROCEEDINGS

         Not applicable.

         (D)    AUDIT COMMITTEE, FINANCIAL EXPERT

         At the present time the Board of Directors does not have an audit
committee financial expert serving on its audit committee. Previously, the
inactive status of the Company did not indicate that an audit / committee
financial expert was required. However, recognizing that the need for such a
financial expert is now necessary, the Board is in the process of obtaining such
an expert to serve on its Board of Directors.

         (E)    IDENTIFICATION OF THE AUDIT COMMITTEE

         The Company does not, at this time, have a separately-designated
standing audit committee. Accordingly, in accordance with the provisions of
section 3(a)(58)(A) of the Exchange Act, the entire Board of Directors is acting
as the Company's audit committee.

         The audit committee has adopted a formal charter specifying (i) the
scope of the audit committee's responsibilities and how to carry out those
responsibilities, including structure, processes and membership requirements,
(ii) receipt from the outside auditor of a formal written statement delineating
all relationships between the auditor and the Company, consistent with
Independence Standards Boards Standard I, and the Committee's responsibility for
actively engaging in communications with the auditor pertaining to any
relationships that may impact the objectivity of the auditor and (iii) items
pertaining to the outside auditor's accountability to the Board of Directors and
the audit committee.

         The audit committee has also adopted guidelines and procedures
consistent with the requirements and standards of Section 301 of the
Sarbanes-Oxley Act of 2002, amending Section 10A of the Securities Exchange Act
of 1934.

         (F)    CODE OF ETHICS

         The Company has adopted a Code of Ethics that applies to the Company's
chief executive officer, principal accounting officer or controller, or
employees of whatever designation performing similar functions.

         For purposes of clarification, the term "code of ethics" means the
written standards that are reasonably designed to deter wrongdoing and to
promote:

         o        Honest and ethical conduct, including the ethical handling of
                  actual or apparent conflicts of interest between personal and
                  professional relationships.

         o        Full, fair, accurate timely and understandable disclosure in
                  the periodic reports required to be filed by the company.

         o        Compliance with applicable governmental laws, rules and


                                       15
<PAGE>

                  regulations.

         o        Prompt internal reporting to the appropriate persons
                  identified in the code of violations of the code; and

         o        Accountability for adherence to the code.

         The full text of the Company's "Code of Business Conduct and Ethics" is
included herein as an Exhibit in Item 13, Exhibit 14, starting at page E-39. The
company will provide to any person without charge a copy of its Code of Business
conduct and Ethics upon receiving a written request therefore at the main office
of the Company, delivered by letter or facsimile form.

ITEM 10. EXECUTIVE COMPENSATION

         (a)   GENERAL

         At this time there is no plan or non-plan compensation awarded to,
earned by, or paid to any executive officer of the Company or any director
thereof.

         (b)   SUMMARY COMPENSATION TABLE

         Not applicable. No executive compensation plan is under consideration.

         (c)   OPTION/SAR GRANTS TABLE

         Not applicable.

         (d)    AGGREGATED OPTION/SAR EXERCISES AND FISCAL YEAR-END OPTIONS/SAR
                VALUE TABLE

         Not applicable.

         (e)    LONG-TERM INCENTIVE PLAN ("LTIP") AWARDS TABLE

         Not applicable.

         (f)    COMPENSATION OF DIRECTORS

         There are no arrangements whatsoever pertaining to compensation for the
directors, including expense reimbursement.

         (g) EMPLOYMENT CONTRACTS AND TERMINATION OF EMPLOYMENT AND
CHANGE-IN-CONTROL ARRANGEMENTS

         Not applicable.


                                       16
<PAGE>

         (h)    REPORT ON REPRICING OF OPTIONS/SAR's

         Not applicable.


ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
         RELATED STOCKHOLDER MATTERS

         (a)    SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION
                PLANS

         None

         (b)    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS

         The table below lists the beneficial ownership of the Company's voting
securities by each person known by the Company to be the beneficial owner of
more than 5% of such voting securities..

<TABLE>
<CAPTION>
                               Name and Address                       Amount and Nature                Percent of
Title of Class                of Beneficial Owner                    of Beneficial Owner                  Class
------------------- ------------------------------------------ ------------------------------ -----------------------------
<S>                 <C>                                        <C>                            <C>
Common              Brett L. DeWees                            2,000,000 shares               33.67%
                    737 SE 1st Way, Apt. 107                   Direct Ownership
                    Deerfield Beach, FL 33441
------------------- ------------------------------------------ ------------------------------ -----------------------------
Common              Bonnie Irby                                500,000                        8.41%
                    737 SE 1st Way, Apt. 107                   Direct Ownership
                    Deerfield Beach, FL 33441
------------------- ------------------------------------------ ------------------------------ -----------------------------
Common              Mycobis Corporation                        2,000,000 shares               33.67%
                    19211 64th Place, NE                       Direct Ownership
                    Kenmore, WA  98028
------------------- ------------------------------------------ ------------------------------ -----------------------------
</TABLE>




         (C)    SECURITY OWNERSHIP OF MANAGEMENT

<TABLE>
<CAPTION>
                                  Name and Address                   Amount and Nature                 Percent of
Title of Class                  of Beneficial Owner                 of Beneficial Owner                  Class
------------------- ------------------------------------------ ------------------------------ -----------------------------
<S>                 <C>                                        <C>                            <C>
Common              Brett L. DeWees                            2,000,000 shares               33.67%
                    737 SE 1st Way, Apt. 107                   Direct Ownership
                    Deerfield Beach, FL 33441
------------------- ------------------------------------------ ------------------------------ -----------------------------
</TABLE>

      Note: No listed beneficial owner has the right to acquire options,
warrants, rights, conversion privileges or similar obligations.


                                       17
<PAGE>

         (D)    CHANGES IN CONTROL

         Not applicable


ITEM 12.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

         Not applicable


ITEM 13.  EXHIBITS

         (a) INDEX TO EXHIBITS

      Exhibit Number     Page Number                 Description
      --------------     -----------                 -----------

         3(i)(a)             E-1                *Articles of Incorporation of
                                                Media Advisory Group, Inc.

         3(i)(b)             E-6                *Certification of Reinstatement

         3(i)(c)             E-7                *Articles of Amendment changing
                                                name to I & E Tropicals, Inc.

         3(i)(d)             E-9                Articles of Amendment changing
                                                name to Viridax Corporation

         3(ii)               E-10               *Bylaws of Viridax Corporation

         10                  E-30               Asset Purchase Agreement

         14                  E-39               Code of Ethics

         31.1                E-41               Certification by President

         32.1                E-43               Certification, 18 U.S.C.

*Incorporated by reference to Form 10-SB/12G, filed 1/7/02.

         (b) REPORTS ON FORM 8-K

         None.

ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

         (A)   Audit Fees

         The aggregate fees billed for professional services rendered for the
audit of annual financial statements included in Form 10-KSB for the fiscal year
ended April 30, 2005 and for the review of quarterly financial statements


                                       18
<PAGE>

included in Form 10-QSB for the quarters ended July 31, 2004, October 31, 2004
and January 31, 2005 were $8,250.

         The aggregate audit fees billed for professional services rendered for
the audit of annual financial statements included in Form 10-KSB for the fiscal
year ended April 30, 2004 and for the review of quarterly financial statements
included in Form 10-QSB for the quarters ended July 21, 2003, October 31, 2003
and January 31, 2004 were $6,675.

         (B) Audit-Related Fees

         None.

         (C) Tax Fees

         The aggregate fees billed in each of the last two fiscal years for
professional services rendered by the principal accountants for tax compliance,
tax advice, and tax planning were $575. The services comprising these fees were
for the preparation of federal and state tax returns

         (D) All Other Fees

         None.

         (E) Pre-Approval Policies

         The Audit Committee is required to pre-approve all auditing services
and permitted non-audit services (including the fees and terms thereof) to be
performed for the Company by its independent auditor, subject to the de minimis
exception for non-audit services described in Section 10A(i)(1)(B) of the
Securities Exchange Act of 1934 that are approved by the Audit Committee prior
to the completion of the audit.


                                       19
<PAGE>

                                   SIGNATURES


      In accordance with the Exchange Act, the registrant caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.


Dated:  June 27, 2005                        By:  /s/  Richard C. Honour
                                                  -----------------------------
                                                  Name:  Richard C. Honour
                                                  Title: President


      In accordance with the Exchange Act, this report has been signed below by
the following persons on behalf of the registrant and in the capacities and on
the dates indicated.



/s/   Richard C. Honour                   President and Director
------------------------------------
Richard C. Honour


/s/   Ledyard H. DeWees                   Secretary
------------------------------------
Ledyard H. DeWees


/s/   Michael C. Maloney                  Director
------------------------------------
Michael C. Maloney


/s/   Javaid Sheikh                       Director
Javaid Sheikh


/s/   Brett L. DeWees                     Director
------------------------------------
Brett L. DeWees





                                       20

<PAGE>

                               VIRIDAX CORPORATION

                          (F/K/A I & E TROPICALS, INC.)

                          (A Development Stage Company)

                              FINANCIAL STATEMENTS

                                 APRIL 30, 2005

<PAGE>

                               VIRIDAX CORPORATION
                          (F/K/A I & E TROPICALS, INC.)
                          (A Development Stage Company)



                                    CONTENTS


                                                                         PAGE

 Independent Auditor's Report                                          F-1

 Financial Statements:

   Balance Sheet                                                       F-2

   Statements of Operations                                            F-3

   Statement of Changes in Stockholders'
   Equity (Deficit)                                                 F-4 to F-5

   Statements of Cash Flows                                         F-6 to F-7

   Notes to Financial Statements                                    F-8 to F-12

<PAGE>

                          INDEPENDENT AUDITOR'S REPORT



To The Board of Directors
Viridax Corporation, F/K/A  I & E Tropicals, Inc.

We have audited the accompanying balance sheet of Viridax Corporation, F/K/A I &
E Tropicals, Inc. (a development stage company), as of April 30, 2005 and the
related statements of operations, changes in stockholders' equity (deficit) and
cash flows for the years ended April 30, 2005 and 2004 and for the period from
July 1, 1998 (inception) through April 30, 2005. These financial statements are
the responsibility of the Company's management. Our responsibility is to express
an opinion on these financial statements based on our audit.

We conducted our audit in accordance with standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audit provides a
reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Viridax Corporation, F/K/A I &
E Tropicals, Inc. (a development stage company) as of April 30, 2005, and the
results of its operations and its cash flows for the years ended April 30, 2005
and 2004 and for the period from July 1, 1998 (inception) through April 30, 2005
in conformity with accounting principles generally accepted in the United
States.

/s/ Earl M. Cohen C.P.A., P.A.
Certified Public Accountant

May 23, 2005
Boca Raton, Florida

                                      F-1


<PAGE>

                               VIRIDAX CORPORATION
                          (F/K/A I & E TROPICALS, INC.)
                          (A Development Stage Company)
                                  BALANCE SHEET
                                 APRIL 30, 2005

                                     ASSETS

CURRENT ASSETS
 Cash                                                                 $   36,106

OTHER ASSET
 Bacteriophage material                                                2,000,000
                                                                      ----------

TOTAL ASSETS                                                          $2,036,106
                                                                      ==========

                              STOCKHOLDERS' EQUITY

TOTAL STOCKHOLDERS' EQUITY                                            $2,036,106
                                                                      ==========

                Read accompanying Notes to Financial Statements.


                                      F-2
<PAGE>

                                                VIRIDAX CORPORATION
                                           (F/K/A I & E TROPICALS, INC.)
                                           (A Development Stage Company)
                                             STATEMENTS OF OPERATIONS


<TABLE>
<CAPTION>
                                                                          July 1,
                                                                           1998
                                       Year Ended      Year Ended      (Inception)
                                        April 30,       April 30,     to April 30,
                                          2005            2004             2005
                                      ------------    ------------    ------------
<S>                                   <C>             <C>             <C>
REVENUE                               $         --    $         --    $        735

EXPENSES
 General and administrative                 12,101           6,790          37,925
                                      ------------    ------------    ------------

NET (LOSS)                            $    (12,101)   $     (6,790)   $    (37,190)
                                      ============    ============    ============

(LOSS) PER SHARE                      $         --    $         --    $       (.01)
                                      ============    ============    ============

WEIGHTED AVERAGE NUMBER OF COMMON
 SHARES OUTSTANDING                      3,919,702       3,900,000       2,517,557
                                      ============    ============    ============
</TABLE>

                Read accompanying Notes to Financial Statements.


                                      F-3
<PAGE>

                          (F/K/A I & E TROPICALS, INC.)
                          (A Development Stage Company)
             STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
           PERIOD FROM JULY 1, 1998 (INCEPTION) THROUGH APRIL 30, 2005


<TABLE>
<CAPTION>
                                                                                         Deficit
                                                                                       Accumulated
                                            Common Stock               Additional       During the
                                      Number of          Par             Paid-In       Development
                                       Shares           Value            Capital           Stage            Total
                                   --------------   --------------   --------------   --------------    --------------
<S>                                <C>              <C>              <C>              <C>               <C>
July 15, 1998 - Common shares
 issued to founders for services
 rendered                               1,000,000   $        1,000   $        4,000   $           --    $        5,000
Net (loss)                                     --               --               --           (5,000)           (5,000)
                                   --------------   --------------   --------------   --------------    --------------
Balance - April 30, 1999                1,000,000            1,000            4,000           (5,000)               --

Net (loss)                                     --               --               --               --                --
                                   --------------   --------------   --------------   --------------    --------------
Balance - April 30, 2000                1,000,000            1,000            4,000           (5,000)               --

Net (loss)                                     --               --               --               --                --
                                   --------------   --------------   --------------   --------------    --------------
Balance - April 30, 2001                1,000,000            1,000            4,000           (5,000)               --

September 2001 - Common shares
 issued for cash                          280,000              280            1,120               --             1,400
October 2001 - Common shares
 issued for cash                        2,620,000            2,620           10,480               --            13,100
Net (loss)                                     --               --               --           (4,343)           (4,343)
                                   --------------   --------------   --------------   --------------    --------------
Balance - April 30, 2002                3,900,000            3,900           15,600           (9,343)           10,157

Net (loss)                                     --               --               --           (8,956)           (8,956)
                                   --------------   --------------   --------------   --------------    --------------
Balance - April 30, 2003                3,900,000            3,900           15,600          (18,299)            1,201

Net (loss)                                     --               --               --           (6,790)           (6,790)
Conversion of net stockholders
 loans to additional paid-in
 capital                                       --               --              245               --               245
                                   --------------   --------------   --------------   --------------    --------------

Balance - April 30, 2004                3,900,000   $        3,900   $       15,845   $      (25,089)   $       (5,344)
</TABLE>




                Read accompanying Notes to Financial Statements.


                                      F-4
<PAGE>

                               VIRIDAX CORPORATION
                          (F/K/A I & E TROPICALS, INC.)
                          (A Development Stage Company)


       STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (CONTINUED)
           PERIOD FROM JULY 1, 1998 (INCEPTION) THROUGH APRIL 30, 2005


<TABLE>
<CAPTION>
                                                                                    Deficit
                                                                                  Accumulated
                                             Common Stock          Additional     During the
                                       Number of         Par         Paid-In      Development
                                        Shares         Value         Capital          Stage           Total
                                     ------------   ------------   ------------   ------------    ------------
<S>                                  <C>            <C>            <C>            <C>             <C>
Balances forward                        3,900,000   $      3,900   $     15,845   $    (25,089)   $     (5,344)

April 2005
 Common shares issued for cash             40,000             40         39,960             --          40,000
 Common shares issued for purchase
 of bacteriophage material              2,000,000          2,000      1,998,000             --       2,000,000
Net (loss)                                     --             --             --        (12,101)        (12,101)
Conversion of notes payable and
 accrued interest and net
 stockholders loans to additional
 paid-in capital                               --             --         13,551             --          13,551
                                     ------------   ------------   ------------   ------------    ------------
Balance - April 30, 2005                5,940,000   $      5,940   $  2,067,356   $    (37,190)   $  2,036,106
                                     ============   ============   ============   ============    ============
</TABLE>


                Read accompanying Notes to Financial Statements.


                                      F-5
<PAGE>

                               VIRIDAX CORPORATION
                          (F/K/A I & E TROPICALS, INC.)
                          (A Development Stage Company)
                            STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>
                                                                                  July 1,
                                                                                   1998
                                                 Year Ended      Year Ended     (Inception)
                                                  April 30,       April 30,     to April 30,
                                                    2005            2004            2005
                                                ------------    ------------    ------------
<S>                                             <C>             <C>             <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
 Net (loss)                                     $    (12,101)   $     (6,790)   $    (37,190)
 Adjustments to reconcile net (loss)
  to cash used in operating activities:
   Common shares issued for services
    rendered                                              --              --           5,000
   Increase in accrued interest                          232             249             576
                                                ------------    ------------    ------------

NET CASH (USED IN) OPERATING ACTIVITIES              (11,871)         (6,541)        (31,614)
                                                ------------    ------------    ------------

CASH FLOWS FROM INVESTING ACTIVITIES:
 Increase in loans receivable - stockholder               --              --         (12,000)
 Repayments of loans receivable - stockholder             --              --           4,000
                                                ------------    ------------    ------------

NET CASH (USED IN) INVESTING ACTIVITIES                   --              --          (8,000)
                                                ------------    ------------    ------------

CASH FLOWS FROM FINANCING ACTIVITIES:
 Proceeds of notes payable                                --              --           5,000
 Issuance of common stock                             40,000              --          54,500
 Increase in amount due to stockholder                 7,975           6,195          16,220
                                                ------------    ------------    ------------

NET CASH PROVIDED BY FINANCING ACTIVITIES             47,975           6,195          75,720
                                                ------------    ------------    ------------

NET INCREASE (DECREASE) IN CASH                       36,106            (346)         36,106

CASH - BEGINNING                                          --             346              --
                                                ------------    ------------    ------------

CASH - ENDING                                   $     36,106    $         --    $     36,106
                                                ============    ============    ============
</TABLE>


                Read accompanying Notes to Financial Statements.


                                      F-6
<PAGE>

                               VIRIDAX CORPORATION
                          (F/K/A I & E TROPICALS, INC.)

                          (A Development Stage Company)
                      STATEMENTS OF CASH FLOWS (CONTINUED)

<TABLE>
<CAPTION>
                                                                               July 1,
                                                                                1998
                                                Year Ended     Year Ended    (Inception)
                                                 April 30,      April 30,    to April 30,
                                                   2005           2004           2005
                                               ------------   ------------   ------------
<S>                                            <C>            <C>            <C>
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING
 AND FINANCING ACTIVITIES:
 Common shares issued for services
  rendered                                     $         --   $         --   $      5,000
                                               ============   ============   ============

 Common shares issued for purchase
 of bacteriophage material                     $  2,000,000   $         --   $  2,000,000
                                               ============   ============   ============

 Conversion of notes payable and accrued
 interest and net stockholders loans to
  additional paid-in capital                   $     13,551   $        245   $     13,796
                                               ============   ============   ============
</TABLE>




                Read accompanying Notes to Financial Statements.


                                      F-7
<PAGE>

                               VIRIDAX CORPORATION
                          (F/K/A I & E TROPICALS, INC.)
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS

                                 APRIL 30, 2005



NOTE 1.           ORGANIZATION

                  Viridax Corporation was incorporated on July 1, 1998 under the
                  laws of the State of Florida as Media Advisory Group, Inc. and
                  on August 6, 2001 changed its name to I & E Tropicals, Inc. On
                  April 5, 2005, the company amended its Articles of
                  Incorporation to change its name to Viridax Corporation. The
                  Company is currently inactive, however, with the purchase of
                  the bacteriophage material referred to in Note 3, the Company
                  is pursuing its plan to expedite the bacteriophage material's
                  commercialization. This bacteriophage material is expected to
                  be used for the treatment of bacterial infections incited by
                  Staphylococcus aureus and other Staphlylococcus species. The
                  Company also intends to continue its business plan for the
                  importing and exporting of exotic marine life and received its
                  wholesale saltwater products license on May 9, 2002. The
                  company's headquarters is in Boca Raton, Florida.

                  The Company has insignificant revenue to date. Since its
                  inception, the Company has been dependent upon the receipt of
                  capital investment or other financing to fund its continuing
                  activities. In addition to the normal risks associated with a
                  new business venture, there can be no assurance that the
                  Company's product development will be successfully completed
                  or that it will be a commercial success. Further, the Company
                  is dependent upon certain related parties to provide continued
                  funding and capital resources.

NOTE 2.           SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

                  Income Taxes

                  Deferred income taxes are provided for differences
                  between the basis of assets and liabilities for financial
                  and income tax reporting.  A valuation allowance is


                                      F-8
<PAGE>

                               VIRIDAX CORPORATION
                          (F/K/A I & E TROPICALS, INC.)
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS

                                 APRIL 30, 2005



NOTE 2.           SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

                  Income Taxes (Continued)

                  provided against deferred income tax assets in circumstances
                  where management believes recoverability of a portion of the
                  assets is not reasonably assured.

                  (Loss) Per Share

                  (Loss) per share is computed by dividing net (loss) for the
                  year by the weighted average number of common shares
                  outstanding.

                  Statement of Cash Flows

                  For purposes of this statement the Company considers all
                  highly liquid investments with an original maturity of three
                  months or less to be cash equivalents. As of April 30, 2005,
                  the Company had no cash equivalents.

                  Use of Estimates

                  Management uses estimates and assumptions in preparing
                  financial statements in accordance with generally accepted
                  accounting principles. Those estimates and assumptions affect
                  the reported amounts of assets and liabilities, the disclosure
                  of contingent assets and liabilities, and the reported
                  revenues and expenses. Accordingly, actual results could vary
                  from the estimates that were assumed in preparing the
                  financial statements and those differences could be material.

NOTE 3.           ASSET ACQUISITION

                  On April 24, 2005 the Company entered into an agreement with a
                  biomedical company to purchase certain Staphylococcus aureus
                  bacteriophages in exchange for 2,000,000 shares of common
                  stock. The bacteriophages were valued at $2 million based upon
                  the Company's most recent


                                      F-9
<PAGE>

                               VIRIDAX CORPORATION
                          (F/K/A I & E TROPICALS, INC.)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                                 APRIL 30, 2005



NOTE 3.           ASSET ACQUISITION (CONTINUED)

                  sale of common stock for cash (Note 6). The Company intends to
                  expedite the commercialization of the bacteriophages by
                  obtaining financing to complete pre- clinical testing and
                  initiate clinical trials in order to obtain regulatory
                  approval for marketing. In the alternative, a market currently
                  exists for the bacteriophage material in certain countries
                  outside the United States.

NOTE 4.           NOTES PAYABLE AND STOCKHOLDER LOANS

                  Notes payable, stockholder loans and accrued interest
                  aggregating $13,551 were converted to additional paid-in
                  capital during the year.

NOTE 5.           INCOME TAXES

                  As of April 30, 2005 and 2004, no deferred income taxes have
                  been recorded due to the Company having no history of
                  profitable operations. Significant components of the Company's
                  net deferred income taxes are as follows:

                                                           2005        2004
                                                         -------    -------

                      Net operating loss carryforwards   $ 5,150    $ 2,950
                      Start-up expenditures                1,750      1,750
                                                         -------    -------
                                                           6,900      4,700
                      Less: Valuation allowance           (6,900)    (4,700)
                                                         -------    -------

                  Net deferred income tax asset          $    --    $    --
                                                         =======    =======

                  During the years ended April 30, 2005 and 2004, the valuation
                  allowance increased by $2,200 and $1,300, respectively.

                  The reconciliation of income tax (benefit) computed at the
                  federal statutory rate to income tax expense (benefit) is as
                  follows:


                                      F-10
<PAGE>

                               VIRIDAX CORPORATION
                          (F/K/A I & E TROPICALS, INC.)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                                 APRIL 30, 2005



NOTE 5.           INCOME TAXES (CONTINUED)

                                                  2005      2004
                                                --------  --------

                  Tax (benefit) at federal
                   statutory rate                 (15.00)%  (15.00)%
                  State tax (benefit), net of
                   federal benefit                 (3.63)    (3.63)
                  Valuation allowance              18.63     18.63
                                                --------  --------

                  Tax provision (benefit)          00.00%    00.00%
                                                ========  ========

                  The Company has net operating loss carryforwards for federal
                  and state purposes of approximately $27,800 available to
                  offset future taxable income. The net operating loss
                  carryforwards, if not used, expire through December 31, 2024.

NOTE 6.           CAPITAL STOCK

                  The Company has 50,000,000 shares of $.001 par value common
                  stock authorized.

                  During April 2005, the Company sold 40,000 shares of common
                  stock for cash at $1 per share exempt from registration under
                  Section 4(2) of the Securities Act of 1933. In addition, the
                  Company issued 2,000,000 shares of common stock for the
                  purchase of bacteriophage material valued at $2 million (Note
                  3).

                  As of April 30, 2005, 5,940,000 shares of common stock were
                  issued and outstanding.

                  Shareholders of common stock have one vote per share.

                  On February 15, 2005, the Company amended its Articles of
                  Incorporation to change the authorized capital stock to add
                  3,000,000 shares of Class A Preferred Stock at a par


                                      F-11
<PAGE>

                               VIRIDAX CORPORATION
                          (F/K/A I & E TROPICALS, INC.)

                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                 APRIL 30, 2005

NOTE 6.           CAPITAL STOCK (CONTINUED)

                  value of $1 per share. The preferred shares are non-
                  cumulative, non-voting and convertible to common shares within
                  the first 3 years under the following schedule: shares
                  converted within the first year of purchase shall receive 4
                  shares of common for every share of preferred; shares
                  converted in the second year after purchase shall receive 4.4
                  shares of common for every share of preferred; shares
                  converted in the third year after purchase shall receive 4.6
                  shares of common for every share of preferred; after 3 years
                  of ownership, the shareholder shall receive 5 shares of common
                  for every share of preferred, but the right to convert must be
                  exercised within 30 days of the 3 year anniversary of purchase
                  or the conversion right will lapse.

                  As of April 30, 2005, no preferred shares were issued and
                  outstanding.


                                      F-12